NTLA
NASDAQ · Biotechnology
Intellia Therapeutics Inc
$12.14
-0.12 (-0.98%)
Open$12.16
Previous Close$12.26
Day High$12.47
Day Low$11.87
52W High$28.25
52W Low$7.95
Volume—
Avg Volume3.84M
Market Cap1.72B
P/E Ratio—
EPS$-3.36
SectorBiotechnology
Analyst Ratings
Buy
24 analysts
Price Target
+167.8% upside
Current
$12.14
$12.14
Target
$32.51
$32.51
$20.88
$32.51 avg
$45.64
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 88.36M | 81.00M | 223.20M |
| Net Income | -538,876,918 | -444,577,162 | -30,251,127 |
| Profit Margin | -609.9% | -579.4% | -13.6% |
| EBITDA | -563,075,435 | -490,348,944 | -52,265,042 |
| Free Cash Flow | — | — | -47,461,783 |
| Rev Growth | +9.1% | +9.1% | +19.1% |
| Debt/Equity | — | — | 0.73 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $264.48 | +0.20% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $393.16 | +1.95% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $150.56 | +0.30% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $510.72 | +0.47% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $798.17 | +1.70% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $244.32 | +1.99% | 40.0 | 32.33B |